Ocugen releases positive preliminary 12-month data from phase 2 ArMaDa trial
Author(s): Martin David Harp Fact checked by: Tracy Ann Politowicz Key Takeaways OCU410 gene therapy showed significant lesion growth reduction in phase 2 trial for geographic atrophy secondary to dry AMD.…